分泌血管活性肠肽的胰腺和神经节神经母细胞瘤（血管活性肠肽瘤）的临床病理研究
Clinicopathological study of pancreatic and ganglioneuroblastoma tumours secreting vasoactive intestinal polypeptide (vipomas).
作者信息
Long R G, Bryant M G, Mitchell S J, Adrian T E, Polak J M, Bloom S R
出版信息
Br Med J (Clin Res Ed). 1981 May 30;282(6278):1767-71. doi: 10.1136/bmj.282.6278.1767.
During a six-year period (1973-9) 52 patients with pancreatic tumours and 10 with ganglioneuroblastomas were found to have raised plasma vasoactive intestinal polypeptide (VIP) concentrations. All the patients had severe secretory diarrhoea, weight loss, dehydration, hypokalaemic acidosis, and a raised plasma urea concentration. Reduced gastric acid secretion was seen in 72% of patients. Plasma VIP concentrations were not raised in patients with diarrhoea due to other types of tumour or disease or in hormone-secreting tumours not associated with diarrhoea. Plasma VIP measurement may therefore give clinical guidance in a patient with persistent watery diarrhoea and hypokalaemic acidosis. Surgical excision was clearly the treatment of choice, but metastatic pancreatic tumours usually responded to streptozotocin.
在六年期间（1973 - 1979年），发现52例胰腺肿瘤患者和10例神经节神经母细胞瘤患者的血浆血管活性肠肽（VIP）浓度升高。所有患者均有严重的分泌性腹泻、体重减轻、脱水、低钾性酸中毒以及血浆尿素浓度升高。72%的患者胃酸分泌减少。因其他类型肿瘤或疾病导致腹泻的患者，以及与腹泻无关的激素分泌性肿瘤患者，其血浆VIP浓度并未升高。因此，血浆VIP检测可为持续性水样腹泻和低钾性酸中毒患者提供临床指导。手术切除显然是首选治疗方法，但转移性胰腺肿瘤通常对链脲佐菌素治疗有反应。
Zotero 插件